Korro Bio, Inc.

Equities

KRRO

US5009461089

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-06-21 pm EDT 5-day change 1st Jan Change
35.38 USD -1.42% Intraday chart for Korro Bio, Inc. -14.95% -26.18%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
HC Wainwright Adjusts Korro Bio's Price Target to $100 From $115, Keeps Buy Rating MT
Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer MT
Korro Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Korro Bio, Inc. Announces the Appointment of Kemi Olugemo, M.D. as Chief Medical Officer CI
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing MT
Korro Bio Insider Bought Shares Worth $999,992, According to a Recent SEC Filing MT
Korro Bio, Inc. announced that it has received $69.959848 million in funding from Atlas Venture L.P., Deep Track Capital, LP, Blue Owl Healthcare Opportunities, Rock Springs Capital Management LP, Tri Locum Partners LP, New Enterprise Associates, Inc. CI
Korro Bio, Inc. announced that it expects to receive $69.959848 million in funding from Atlas Venture L.P. CI
HC Wainwright Adjusts Korro Bio's Price Target to $115 From $100, Buy Rating Kept MT
RBC Boosts Price Target on Korro Bio to $90 From $70 on 'Increased Conviction for A1AT,' Keeps Outperform, Speculative Risk MT
Korro Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
North American Morning Briefing : Stocks Struggle After New Records DJ
North American Morning Briefing : Inflation -2- DJ
BMO Capital Initiates Korro Bio With Outperform Rating, Price Target is $120 MT
Korro Announces Selection of Its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency CI
HC Wainwright Starts Korro Bio With Buy Rating, $100 Price Target MT
RBC Initiates Korro Bio at Outperform, Speculative Risk With $70 Price Target, Says Lead Program 'May Be Best-in-Class' for A1AT Protein MT
Korro Bio, Inc. Appoints Rachel Meyers as Board of Directors, Member of Nominating and Corporate Governance Committee CI
Piper Sandler Starts Coverage on Korro Bio with Overweight Rating, $180 Price Target MT
Frequency Therapeutics, Inc.(NasdaqCM:FREQ) dropped from NASDAQ Composite Index CI
Chart Korro Bio, Inc.
More charts
Korro Bio, Inc. is a biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Its Oligonucleotide Promoted Editing of RNA (OPERA) is a foundational platform for RNA editing, which is designed to edit RNA in vivo by delivering an oligonucleotide guide that can target specific RNA sequences. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD), that has the potential to be disease-modifying and provide a differentiated therapeutic option.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
35.38 USD
Average target price
126.2 USD
Spread / Average Target
+256.84%
Consensus
  1. Stock Market
  2. Equities
  3. KRRO Stock
  4. News Korro Bio, Inc.
  5. Korro Bio Q1 Net Loss Shrinks; Kemi Olugemo Appointed as Chief Medical Officer